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Background: Hemorrhage is the leading direct cause of maternal death globally. While oxytocin is the drug of
choice for postpartum hemorrhage prevention, its use has generally been limited to health facilities. This trial
assesses the effectiveness, safety, and feasibility of expanding the use of prophylactic intramuscular oxytocin to
peripheral health care providers at home births in four predominantly rural districts in central Ghana.
Methods: This study is designed as a community-based cluster-randomized trial in which Community Health
Officers are randomized to provide (or not provide) an injection of oxytocin 10 IU via the UnijectTM injection system
within one minute of delivery of the baby to women who request their presence at home at the onset of labor.
The primary aim is to determine if administration of prophylactic oxytocin via Uniject™ by this cadre will reduce the
risk of postpartum hemorrhage by 50 % relative to deliveries which do not receive the prophylactic intervention.
Postpartum hemorrhage is examined under three sequential definitions: 1) blood loss ≥500 ml (BL); 2) treatment for
bleeding (TX) and/or BL; 3) hospital referral for bleeding and/or TX and/or BL. Secondary outcomes address safety
and feasibility of the intervention and include adverse maternal and fetal outcomes and logistical concerns
regarding assistance at home births and the storage and handling of oxytocin, respectively.
Discussion: Results from this trial will build evidence for the effectiveness of expanding the delivery of this
established prophylactic intervention to peripheral settings. Complementary data on safety and logistical issues
related to this intervention will assist policymakers in low-income countries in selecting both the best uterotonic
and service delivery strategy for postpartum hemorrhage prevention. Results of this trial are expected in mid-2013.
The trial is registered at ClinicalTrials.gov: NCT01108289.
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Figure 1 The oxytocin in UnijectTM injection system.
Source: PATH/Glenn Austin.
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An estimated 350,000 women die each year in childbirth.
Progress in reducing maternal mortality has been varied
within and between regions, with the least progress in
sub-Saharan Africa [1]. The leading direct cause of ma-
ternal death worldwide is hemorrhage [2] and it is gen-
erally accepted that the majority of these hemorrhages
occur during the postpartum period, predominantly
from uterine atony. Active management of the third
stage of labor (AMTSL)— defined as intramuscular
administration of 10 international units (IU) of oxyto-
cin, controlled cord traction, and fundal massage—
substantially reduces the risk of postpartum hemorrhage
(PPH). A meta-analysis from four facility-based clinical
trials showed a 62 % reduction in the risk of PPH (blood
loss ≥500 mL) associated with AMTSL [3]. Given the
strength of the evidence, the World Health Organization
(WHO), the International Federation of Gynecology and
Obstetrics (FIGO), and the International Confederation
of Midwives (ICM) all recommend AMTSL provided by
a skilled birth attendant for all singleton births [4,5].
Oxytocin is a naturally occurring hormone which pro-
motes smooth muscle contraction. When released post-
partum it stimulates both the breastmilk let-down reflex
and uterine contraction to slow and stop blood loss. Its
synthetic analogue is the recommended uterotonic drug
of choice for AMTSL, due to its rapid onset of action,
minimal side effects, and low cost [5].
In the absence of a skilled birth attendant, WHO
recommends that a uterotonic (i.e., oxytocin or miso-
prostol) should be given by a health worker trained in its
use to prevent PPH. Oxytocin is preferred over miso-
prostol where its use is feasible [6]. While misoprostol
has been shown to be effective in preventing PPH at the
community level [7-9], in facility-based studies, its effi-
cacy is lower than that achieved by oxytocin and is asso-
ciated with side effects, including shivering and pyrexia
[10]. As Buekens notes, “both drugs have their place in
the prevention and treatment of PPH. However, oxytocin
is the drug of choice and every effort should be made to
make it widely accessible, including at the community
level” [11].
Thus, research is needed to assess the safety and feasi-
bility of expanding access to this drug. Expanding
provision of oxytocin to peripheral settings raises three
main concerns: (1) providers may not be skilled in giving
injections, (2) heat exposure may compromise drug integ-
rity/potency, and (3) administration prior to delivery of
the baby (i.e., for induction and/or augmentation) outside
a fully qualified facility increases risk to mother and baby.
The use of oxytocin in the UnijectTM injection system
addresses the first of these concerns. The injection sys-
tem (Figure 1) is an autodisable, “all-in-one” injection
system prefilled with the required dosage of drug—inthis case, a single dose of oxytocin 10 IU. The injection-
ready format reduces wastage, simplifies logistics, and
allows use both by lay health personnel who do not nor-
mally administer injections and in areas with limited
health infrastructure [12]. Oxytocin 10 IU in UnijectTM
has been used in observational studies with doctors and
midwives at hospitals in Angola and Latin America [13-
15], and with birth attendants in the community or
lower- level health facilities in Indonesia [16], Mali [17],
and Vietnam [18,19]. In these observational studies
across multiple settings and cadres of health workers,
oxytocin in UnijectTM has been found to be well toler-
ated and easy to use and has a high level of acceptability
among providers.
The second concern is alleviated by adding a time-
temperature indicator (TTI) to the foil pouch containing
each Uniject™ injection system (Figure 2). This indicator
provides a qualitative measure of cumulative heat expos-
ure by changing color to indicate when the injection sys-
tem should no longer be used. Studies have shown that
oxytocin loses 14 % of its chemically active ingredient
when stored at 30°C for one year [20]. The TTI expands
the use of oxytocin to the periphery by ensuring that
even lay users are able to easily assess if a specific dose
is still potent.
Given that a simple injection system is now available
which facilitates safe administration of chemically potent
oxytocin, a drug known to be effective at PPH preven-
tion when administered by medical personnel in health
facilities, the question remains whether this intervention
is effective, safe, and feasible in the hands of a minimally
trained health care provider assisting home births. This
trial, conducted as part of the Oxytocin Initiative project,
is designed to address this question.
Methods/Design
This study is designed as a cluster-randomized commu-
nity-based trial in which Ghana Health Service (GHS)
Figure 2 The Oxytocin in UnijectTM package, including a time-temperature indicator, with an enlarged example of time-temperature
indicator colors. Source: C. Stanton.
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into one of two study arms determining the care that
CHOs provide to enrolled women during their home-
based deliveries. For the purposes of this trial, all deliver-
ies assisted by an individual CHO constitute a cluster.
The trial is designed to determine if intramuscular ad-
ministration of 10 IU of oxytocin in Uniject™ during the
third stage of labor by a CHO will reduce the risk of
PPH by 50 % relative to deliveries attended by a CHO
who does not provide the prophylactic intervention. This
is not, however, a drug efficacy trial. The trial is designed
to assess the mode of service delivery.
Implementation of the trial is divided into three
phases. The first phase is designed as a month-long Ac-
tive Preparation Phase in which all field procedures and
data collection systems are activated except administra-
tion of oxytocin by CHOs. The Comparative Phase
marks the initiation of enrollment into the trial and was
originally planned to last nine months. The third phase
of the trial is a conditional three month Universal Distri-
bution Phase in which all women enrolled in the trial
would receive prophylactic oxytocin following delivery
of the baby. Implementation of the Universal Distribu-
tion Phase of the trial is conditional upon results of the
Comparative Phase and feedback from the Data Safety
and Monitoring Board.
Study site
The trial is being conducted in four predominantly rural
districts of Brong-Ahafo region in central Ghana. The
study districts, which are under demographic surveil-
lance by the Kintampo Health Research Centre (KHRC),
are Kintampo North and South and Nkoranza North
and South (Figure 3), with a combined population of ap-
proximately 260,000. KHRC is a field research center op-
erating since 1994 under the GHS and responsible for
many large-scale, prospective clinical and community-
based trials. The selected districts are an excellent con-
text in which to assess home-based PPH preventionbecause maternal mortality in this area is high (at ap-
proximately 350 to 400 maternal deaths per 100,000
pregnancies [21]) and approximately 30 % of births
occur at home.
Field staff
Field staff for this trial consist of 69 field workers, with
at least senior-high school education, dedicated to this
study and resident in the communities for which they
are responsible, and nine field supervisors. The field
workers were provided with bicycles and the supervisors
were provided with motorcycles to facilitate movement
within their areas of work. All field staff participated in a
three-day training prior to the start of the study.
Extensive consultations were required during the de-
sign phase of the study between KHRC leadership, study
investigators, and GHS staff at both the district and re-
gional levels regarding the involvement of GHS CHOs
as the agents to administer the study intervention.
CHOs are the centerpiece of the GHS Community-based
Health Planning and Services (CHPS) Initiative, which
has the goal of expanding access to basic health care for
the rural population. CHO services include childhood
vaccination, antenatal and postnatal care, family plan-
ning outreach, emergency deliveries, and referral for
complications during pregnancy and delivery. While
CHOs are permitted to administer ergometrine tablets
in an emergency for treatment of postpartum
hemorrhage, they are not currently permitted to admin-
ister injectable uterotonics. Following training, CHOs
are posted to a CHPS compound from which their clin-
ical and outreach work is based.
The study facilitated the placement of CHOs into
communities in study districts where there were no
CHOs and provided resources to improve CHO com-
pounds where these were inadequate. Prior to the start
of the study, all CHOs completed a five-day training
course and were required to pass a competency-based
examination specific to their cluster allocation.
Figure 3 Maps of Nkoranza and Kintampo Districts, Brong-Ahafo Region, Ghana.
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with some allowance to purchase credit for their mobile
phones as well as basic comfort items such as solar
lamps and beds. The compounds are also provided with
basic hospital equipment such as examination couches
and cupboards for storage of medical supplies as a con-
tribution to the expansion of the CHPS initiative. Study-
related work by the CHOs is jointly supervised by the
GHS and KHRC.
Randomization
Among the four participating districts, 52 CHO areas were
identified and categorized as either “near” (≤ 10 km) andTable 1 Number of CHOs randomly allocated to OIU and com
stratified on district and distance from facility
District Near (≤10 km)
Oxytocin in UnijectTM Comp
Kintampo North 3 3
Kintampo South 5 5
Nkoranza North 2 2
Nkoranza South 2 2“far” (> 10 km) from a facility with capacity for emergency
obstetric care. The categorization resulted in eight strata (4
district x 2 distance), two of which contained an odd num-
ber (n=7, 7) and six of which contained an even number
of CHOs (n=6, 10, 4, 4, 8, 6). A temporary placeholder
CHO was added to each of the two strata containing an
odd number of CHOs, and all units were randomly allo-
cated to either the oxytocin in UnijectTM group or the
Comparison group using the STATA utility “ralloc” [22],
stratified on district and distance. This random allocation
was repeated 10,000 times. Among the 4,995 allocation
sequences that assigned the placeholder CHOs to opposite
groups, a single allocation was selected at random, and theparison groups as a result of randomization procedure
Far (>10 km)





Figure 4 Flowchart of trial design.
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Figure 5 Training exercise for use of the BRASSS-V blood
collection drape. The individuals pictured gave consent for this
image to be published.
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total CHOs evenly allocated overall (26 vs. 26), within each
of the six strata with an even number of CHOs, and in a
ratio of 4:3 and 3:4 in the two strata with an odd number
of CHOs (Table 1).
Figure 4 describes the flow of all trial activities from
randomization through blood loss measurement.
Procurement of oxytocin in UnijectTM
Oxytocin in Uniject™ injection devices with time-
temperature indicators were produced by Instituto Bio-
lógico Argentino (BIOL), a pharmaceutical producer in
Argentina, and imported into Ghana as clinical study
supplies after obtaining a clinical sample import permit
from the Ghana Food and Drug Board. They are trans-
ported to KHRC under cold chain conditions and are
distributed from KHRC refrigerators on a weekly or as-
needed basis to CHOs, who store them in their com-
pounds in a cool place. Storing oxytocin out of the cold
chain is being done to ensure that the intervention is
being conducted under conditions as similar as possible
to a scaled-up government service. To the best of our
knowledge, this study constitutes the first randomized
controlled trial in which the oxytocin in UnijectTM injec-
tion system has been used.
Recruitment
Prior to the start of field work, community meetings
were held with GHS authorities in various communities,
opinion leaders, chiefs, and community members
regarding the objectives of the study. KHRC field work-
ers then began identifying on a weekly basis all house-
holds with a pregnant woman within their allotted
communities. There are no exclusion criteria for this
study. As pregnant women at seven months or more
gestation are identified, the study is explained to them
and they are asked for initial consent to participate in
the study. Initial consent indicates that a woman is inter-
ested in having a CHO present at her delivery should
she be unable to travel to a health facility or should she
choose to deliver at home. Field workers remain in con-
tact with women who have initially consented, and
where possible, they arrange to introduce the CHO to
the pregnant woman’s family. They then wait to see if
the woman calls the field worker at the onset of her
labor. When field workers are contacted, they phone the
CHO and both travel to the woman’s household, al-
though the field worker will generally remain outside of
the house. Final consent for full participation is obtained
at this time.
Trial implementation
Once in the home and after administration of final con-
sent, CHOs in both groups place a BRASSS-V calibrateddrape designed to collect postpartum blood under the
woman’s body before birth of the baby. Women are
asked to remain recumbent, if possible, for one hour if
bleeding ceases within one hour, or for two hours if ac-
tive bleeding continues at one hour. The blood loss
measure excludes fluid, urine, and feces passed during
the birthing process. All blood collected in the drape is
scooped into the pouch. The drape is removed from the
woman and held up vertically in order to obtain the
blood loss reading (Figure 5). This method has been vali-
dated and used in a number of previous and ongoing
trials [23]. If a woman in either arm of the trial is ac-
tively bleeding when she has lost 400 mL blood, referral
is initiated via mobile phone for emergency transport.
To identify active bleeding, all CHOs are trained to
monitor pulse, uterine tone, and vaginal bleeding every
15 minutes for the first two hours after delivery of the
baby. Study-sponsored vehicles and drivers specifically
available for this purpose immediately respond to emer-
gency calls. In the event of PPH (defined as ≥ 500 mL
blood loss) early treatment with one injection of 10 IU
of oxytocin and fundal massage will be provided by the
CHO. This same treatment response may also be pro-
vided in the event of gushing blood, a uterus that is nei-
ther hard nor round, and/or blood clots the size of a
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ond twin is done prior to all injections of oxytocin.
Emergency referral and transport is available to women
and newborns in both arms of the study for any type of
complication.
The intervention
While all CHOs measure blood loss and provide treat-
ment and referral (if necessary), CHOs randomized to
the intervention arm provide one injection of 10 IU of
oxytocin administered via UnijectTM in the thigh within
one minute after delivery of the baby. CHOs in both
arms collaborate with the birth attendant to conduct
their study-related responsibilities and do not directly
manage the delivery.
Follow-up
Two to three days following delivery, the field worker
visits the house of all enrolled women for a follow-up
interview with questions regarding the care they
received, and in particular, the timing relative to delivery
of the baby of any injections they may have received.
When necessary, a family member who was present dur-
ing the birth may assist in responding to these questions.
In cases where traditional birth attendants managed the
delivery, a similar interview is also conducted with them.
Sample size estimation
The sample size estimation procedure followed a stand-
ard approach for cluster-randomized trials [24]. First,
having a priori determined that the desired recruitment
period for the comparative phase of the trial would be
9 months, we estimated the expected mean number of
observed deliveries per CHO over this time period
(mean cluster size = 24), derived from available estimates
of (1) the crude birth rate (27 per 1,000), (2) the mean
population size covered by a CHO (4,250), and (3) the
total proportion of deliveries that would be conducted at
home and reachable by CHOs (28 %). Second, in the ab-
sence of prior information on the incidence of PPH in
this setting, we estimated from a previous community-
based trial in rural India that the observed frequency of
PPH among women delivering in the presence of com-
parison CHOs would be approximately 10.0 %, and we
assumed a conservatively high variation coefficient
(“k”= 0.35) across CHOs. Setting the Type I error rate to
5 % and assuming 10 % loss per cluster, we estimated
that 26 CHOs (or 564 pregnancies) would be required
within each group (i.e., total = 1128) in order to detect
reductions in PPH of 50 % or more with at least 80 %
power. After the actual pace of enrollment was estab-
lished (~August 2011), we re-estimated that the time to
reach this initially estimated sample size of 1128 would
require 12 months of recruitment.Data management
CHOs, KHRC field workers, and supervisors collected
data using paper-based forms during their contacts with
pregnant women and family members. These included a
Background Information form filled at the time of the
preliminary consent (approximately seven months gesta-
tion); a CHO form filled at and soon after the observed
delivery; and follow-up forms with the delivered woman,
a family member, and, if present, the traditional birth at-
tendant that assisted at the time of delivery. All forms
filled by CHOs and field workers were checked by super-
visors for completeness and consistency, and then trans-
ferred to the KHRC Computer Center for double data
entry into a customized Visual FoxPro database.
Consistency, validity, and referential integrity are
enforced through automated post-entry checks on the
database. Basic enrollment status reports are generated
fortnightly.
Data analysis
Both the interim and final analyses will begin with de-
scriptive information regarding the extent (i.e., total
numbers) of enrollment, the dynamic of enrollment over
the period of the trial, and variation between the clusters
in terms of enrollment. Given the importance of asses-
sing feasibility of this intervention in any scaled-up pro-
gram, particular focus will be placed on describing the
frequency with which women in labor contact the CHO
to request her presence and the proportion of these
women for whom the CHO arrives before delivery. Rea-
sons for not contacting the CHO or for non-arrival by
the CHO will be estimated and compared across the
groups. Enrolled women will be defined as those for
whom (1) the field worker/CHO arrived at the home
prior to delivery, (2) consent to participate was recon-
firmed ("final consent"), and (3) the CHO was present at
the home of the woman at the time of delivery. Among
enrolled women, a range of covariates will be compared
to determine if the cluster randomization achieved bal-
ance across socio-economic, household, and maternal
characteristics.
Primary outcome
The primary outcome of this trial is PPH. This outcome
was selected based on (1) extended discussions with an
international technical advisory group established for the
study, which concluded that for policy impact, it would
be insufficient to assume a health benefit from this inter-
vention given the use of minimally trained health care
providers and use of a new technology; (2) a general
consensus that blood loss equal to or greater than
500 mL constitutes PPH; and (3) the availability of a
validated tool for the measurement of blood loss in a
home setting.
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(Table 2). The strictest definition will be cumulative
blood loss of ≥ 500 mL as measured by the BRASSS-V
drape at the end of the first hour after birth, or in the
case of active bleeding at one hour, at the end of the sec-
ond hour after birth. Under this definition, all women
who have blood loss measured will be included; those
with ≥ 500 mL will be included in the numerator and all
others with a quantitative measure will be in the denom-
inator. Two further definitions will be examined, given
that this strict definition is problematic in two ways.
First, some women (in both groups) will be provided a
treatment dose either before one hour is complete, or
prior to reaching 500 mL; this dose could obscure the
total amount of blood loss that might have occurred in
the absence of this rapid treatment response. Therefore,
a second broader definition will include in the numer-
ator all women with ≥ 500 mL measured blood loss OR
women receiving a treatment dose of oxytocin (regard-
less of final measured blood loss) and will be assessed
among all enrolled women. Furthermore, some women
may be referred by the CHO for postpartum blood loss,
yet not be included in the numerator (or the denomin-
ator) of either the prior two definitions. Thus, the final
definition will include in the numerator all women with
one or more of the criteria (≥ 500 mL blood loss, receipt
of a treatment dose, referral for blood loss) and will be
assessed among all enrolled women.
Analysis of each of these three definitions will follow
an intent-to-treat approach; that is, enrolled women will
be included in the analysis according to their cluster al-
location, regardless of their specific receipt (or non-
receipt) of the assigned intervention. Separately for each
definition, the proportion of women in each group meet-
ing the criteria will be estimated, and the risk of the out-
come in the intervention group relative to the control
group will be calculated (i.e., risk ratio) using a binomial
regression model with log link function. Standard errors
will be adjusted for the clustered allocation using the
generalized estimating equation approach [25], and 95 %
confidence intervals will be estimated. If necessary, re-









3 ✓ ✓ ✓between the groups, previously identified during the de-
scriptive analysis phase.
Secondary outcomes
Given concerns regarding the safety of the intervention
and its programmatic feasibility, several secondary out-
comes were selected. The predominant safety concern is
administration of oxytocin for induction, or more likely,
for augmentation of labor. Use of any intramuscular
uterotonic drug before the birth of the infant is regarded
as dangerous because it is not possible to adjust the dos-
age if it causes hyperstimulation and cannot be adapted
to the level of uterine activity, as is possible with the
monitored administration of intravenous oxytocin in
health facilities [26]. Hyperstimulation of the uterus can
lead to uterine rupture, fetal asphyxia or fetal demise
[27,28]. Thus, the key secondary outcome for this trial is
mistimed use of oxytocin, and will be defined as any use
of oxytocin prior to delivery of the (last) baby. The pro-
portion of deliveries in which a CHO, traditional birth
attendant, or pregnant woman/family member reports
that oxytocin in UnijectTM was given prior to delivery of
the (last) baby will be estimated, and a 95 % confidence
interval constructed. If appropriate, this outcome will be
examined separately by allocation group and compared
using standard methods (again, adjusting standard errors
for cluster randomization).
Other safety outcomes include individual and compos-
ite estimates of the frequency of adverse maternal, fetal,
and neonatal events, including maternal deaths, still-
births, early neonatal deaths, birth asphyxia, need for
newborn resuscitation, uterine rupture, and referral and/
or transport to a higher-level facility. Among participat-
ing women, comparisons will be made for all deliveries
across both arms of the trial and also restricted to deliv-
eries for which oxytocin was given before delivery of the
baby. For each comparison (and the composite meas-
ure), proportions will be estimated, and 95 % confidence
intervals constructed. Comparisons across groups will
utilize binomial regression with a log link function, will
account for clustered allocation using GEE, and will ad-






- observed blood loss
≥500 mL
Has quantitative
measure of blood loss
- observed blood loss
≥500 mL - received
treatment dose
Has quantitative
measure of blood loss
- observed blood loss
≥500 mL - received
treatment dose - CHO
referred for blood loss
All enrolled women
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portions, means, etc.). These include, among others, the
proportion of deliveries in which the CHO arrives late,
the mean time between call and arrival of the CHO, pro-
portion of participating pregnancies (initial consent
given) that become participants (final consent given),
and the proportion of oxytocin in UnijectTM injection
systems disposed of properly.
Data Safety and Monitoring Board and interim analyses
An independent Data Safety and Monitoring Board
(DSMB) consisting of national and regional experts was
established. Stopping guidelines for efficacy were agreed
upon by the DSMB members and the investigating team
prior to the trial, using Lan-DeMets boundaries and
nominal p-values for group sequential analyses estimated
using O’Brien-Fleming spending function [29,30]. A sin-
gle interim analysis was conducted at ~47 % of the ini-
tially planned overall recruitment (December 2011). At
the interim analysis, the DSMB recommended continu-
ation of the trial, and suggested extending total enroll-
ment to the extent possible given available resources.
Based on this recommendation, the trial was approved
for a sample size of 1850 women with data collection
continuing for a total of 18 months of recruitment.
Approvals and registration
The study protocol was approved by the KHRC and
GHS Ethical Review Committees, the Institutional Re-
view Board of the Johns Hopkins Bloomberg School of
Public Health (#00002673), and the Research Ethics
Committee of PATH (#547). The protocol is reviewed
and reapproved on an annual basis. The trial is regis-
tered at ClinicalTrials.gov: NCT01108289.
Discussion
Programmatic responses to PPH prevention must take
into account contextual issues, including health care
provider skills, location, and authorizations for use of
specific drugs and modes of administration. Drug effect-
iveness, PPH treatment options, drug and service deliv-
ery costs, and logistical constraints are all important
considerations. This trial is designed to address many of
these questions for prophylactic oxytocin administered
via the UnijectTM injection system.
PPH (defined via blood loss measurement or clinical
signs) was selected as the primary outcome of the study
for reasons described above. Blood loss data and clinical
signs are being used as triggers to initiate early treat-
ment of PPH, and in the case of clinical signs, treatment
is initiated without regard to blood loss. Given that PPH
is extremely time-sensitive, CHOs are not skilled birth
attendants, infrastructure in many areas is poor, and
some study households are in remote locations, waitingto initiate treatment until blood loss reached 500 mL or
more (as has been done in some health facility-based
trials [31,32] was not considered ethically acceptable.
Consequently, the low threshold required for early treat-
ment of PPH for some women may have influenced
observed blood loss. This is the basis for including
broader definitions of blood loss described above and
included in Table 2.
The priority for this study design is to conduct a
methodologically rigorous study that ensures the safety
of all study participants and that yields valid results
regarding the risks and benefits of expanding use of a
known, effective lifesaving drug for prevention of PPH.
Results of this trial are expected in 2013, and will inform
national and international PPH prevention policy and
guideline development.
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